Substantial age-adjusted reductions in cardiovascular mortality and morbidity over the past few decades are being challenged by increases in physical inactivity, diabetes mellitus, and obesity, creating a large and aging population with long-term cardiovascular disease (CVD). However, the US national investments in discovery and translational science1 continue to produce major advances, both in understanding these conditions at the cellular level and in development of therapeutic and diagnostic tools that can improve health outcomes.